HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs

Launched by IRCCS NATIONAL NEUROLOGICAL INSTITUTE "C. MONDINO" FOUNDATION · Nov 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific treatment for migraines, called monoclonal antibodies (mAbs), affects the brain's activity in people who suffer from chronic or episodic migraines. The researchers want to see if these treatments change the way different parts of the brain connect and communicate with each other. Migraines can be very disabling, and this study aims to better understand the effects of these new therapies on brain function.

To participate in the trial, individuals must be between the ages of 18 and 65 and have a diagnosis of episodic or chronic migraine. They should also have had a brain MRI in the last two years. However, people with certain conditions, like a history of epilepsy, psychiatric illnesses, or those who are pregnant, cannot take part in the study. Participants will undergo a procedure called high-density EEG, which records brain activity, to help researchers learn more about how the treatment works. This study is currently looking for volunteers, and it could provide valuable insights into improving migraine treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Episodic or chronic migraine diagnosis according to ICHD-3 criteria
• • Indication to BoNT-A or mAbs treatment according to AIFA criteria
• • Brain MRI performed within 24 months from enrolment
• Exclusion Criteria:
• • Previous or actual history of epilepsy
• • Diagnosis of dementia o mental retardation
• • Diagnosis of psychiatric illness according to Diagnostic and Statistical Manual of Mental Disorders V
• • Other concomitant type of headache (except for sporadic tension type headache)
• • Chronic pain conditions
• • Pregnancy or breastfeeding
• • Concomitant use of electrical stimulators, pace-makers, metallic clips or other metallic foreign bodies
• • Previous head surgery
• • Ongoing neuroactive prevention therapies or other drugs, or psicoactive substances possibly interfering with EEG recording (eg benzodiazepines)
• • Other conditions possibly influencing EEG recording
• • Brain anomalies detected on MRI